301207.SHE Hualan Biological Bacterin Inc.
- Market cap
- CNY 8.38B
- P/E
- 174.4x
- P/B
- 1.62x
- ROE
- -0.1%
- Dividend yield
- 6.06%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301207.SHE undervalued?
Graham numberThe Graham number of Hualan Biological Bacterin Inc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hualan Biological Bacterin Inc. fundamental analysis
No fundamental analysis for Hualan Biological Bacterin Inc. yet.
Hualan Biological Bacterin Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hualan Biological Bacterin Inc.
Hualan Biological Vaccine Inc. engages in the research and development, production, and sale of vaccines and genetically engineered biological products in China. The company's main products include influenza virus split vaccine, quadrivalent influenza virus split vaccine, quadrivalent influenza virus split vaccine (pediatric formulation), H1N1 influenza A virus split vaccine, ACYW135 group meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine (Hansenula polym…
Full company profileHualan Biological Bacterin Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hualan Biological Bacterin Inc. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 285M | 803M | 1.05B | 2.43B | 1.83B | 1.83B | 2.41B | 1.13B | 1.20B | 401M |
| Gross Profit | 166M | 673M | 838M | 2.14B | 1.48B | 1.46B | 2.03B | 841M | 936M | 251M |
| Operating Income | -101M | 300M | 432M | 1.07B | 707M | 593M | 1.01B | 215M | 188M | -143M |
| EBITDA | 179M | 604M | 765M | 1.12B | 787M | 735M | 1.15B | 361M | 331M | -143M |
| Net Income | -76.9M | 270M | 375M | 925M | 621M | 520M | 860M | 206M | 183M | -5.93M |
| EPS | -0.14 | 0.50 | 0.69 | 1.71 | 1.15 | 0.88 | 1.43 | 0.34 | 0.30 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 846M | 1.37B | 1.79B | 3.65B | 4.52B | 7.08B | 8.00B | 7.52B | 6.84B | 6.27B |
| Total Liabilities | 229M | 481M | 532M | 1.46B | 1.72B | 1.58B | 1.73B | 1.51B | 1.14B | 1.11B |
| Shareholders' Equity | 617M | 887M | 1.26B | 2.19B | 2.81B | 5.50B | 6.26B | 6.01B | 5.70B | 5.16B |
| Cash & Short-term Investments | 26.6M | 143M | 501M | 865M | 957M | 2.02B | 2.61B | 2.08B | 353M | 567M |
| Total Debt | - | - | - | 200M | 502M | 300M | 300M | 300M | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 22.2M | 94.5M | 275M | 694M | 569M | 289M | 888M | 468M | 357M | - |
| Capital Expenditure | 25.6M | 62.8M | 144M | 532M | 636M | 92.6M | 62.6M | 51.6M | 9.70M | 20.0M |
| Free Cash Flow | -3.43M | 31.7M | 131M | 161M | -66.7M | 196M | 825M | 416M | 347M | 270M |
| Ratios | ||||||||||
| ROE | -12.5% | 30.5% | 29.7% | 42.3% | 22.1% | 9.5% | 13.7% | 3.4% | 3.2% | -0.1% |
| ROA | -9.1% | 19.7% | 20.9% | 25.4% | 13.7% | 7.3% | 10.8% | 2.7% | 2.7% | -0.1% |
| Net Profit Margin | -27.0% | 33.7% | 35.8% | 38.1% | 33.9% | 28.5% | 35.7% | 18.2% | 15.2% | -1.5% |
| Debt to Equity | - | - | - | 0.09x | 0.18x | 0.05x | 0.05x | 0.05x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hualan Biological Bacterin Inc. dividends
- Dividend yield
- 6.06%
- Forward dividend
- 1.40 CNY
- Payout ratio
- 277.7%
- Ex-dividend date
- Jun 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 508M | 0.85 | 277.7% |
| 2024 | CNY 334M | 0.56 | 162.7% |
| 2023 | CNY 126M | 0.21 | 14.7% |
| 2022 | CNY 90.9M | 0.15 | 17.5% |
| 2021 | CNY 12.8M | 0.02 | 2.1% |
| 2020 | CNY 4.59M | 0.01 | 0.5% |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | 100M | 0.19 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on Jun 7, 2023.
Who owns Hualan Biological Bacterin Inc.
- Insiders 83.06%
- Institutions 0.64%
- Public & others 16.31%
- Shares outstanding 601M
- Free float 96.2M
Hualan Biological Bacterin Inc. company profile
- Company name
- Hualan Biological Bacterin Inc.
- Ticker
- 301207.SHE
- ISIN
- CNE1000058J9
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 708
- Fiscal year end
- December
- Address
- Jia No. 1-1, Hualan Avenue, Xinxiang, China, 453003
- Phone
- 86 37 3355 9909
- Website
- hualanbacterin.com
About Hualan Biological Bacterin Inc.
Hualan Biological Vaccine Inc. engages in the research and development, production, and sale of vaccines and genetically engineered biological products in China. The company's main products include influenza virus split vaccine, quadrivalent influenza virus split vaccine, quadrivalent influenza virus split vaccine (pediatric formulation), H1N1 influenza A virus split vaccine, ACYW135 group meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine (Hansenula polymorpha), group A and C meningococcal polysaccharide vaccine, freeze-dried human rabies vaccine (Vero cells), and adsorbed tetanus vaccine. It also offers products under development, such as freeze-dried Group A and Group C meningococcal conjugate vaccine, adsorbed cell-free tridiphtheria-tetanus combined vaccine, freeze-dried Haemophilus influenzae type b conjugate vaccine, and recombinant zoster vaccine (CHO cells), mRNA influenza vaccines, adsorbed tetanus vaccine, and novel adjuvanted influenza vaccines. In addition, it sells self-produced products. The company was founded in 2005 and is based in Xinxiang, China.
Hualan Biological Bacterin Inc. management
3- Ms. Wenjue AnGM & Director · born 1989
- Mr. Ke LuCFO & Secretary · born 1984
- Ms. Ruowen PanExecutive VP & Director · born 1968